Thomas J Swope, MD | |
301 Saint Paul Pl, Pob 912, Baltimore, MD 21202-2102 | |
(410) 332-9653 | |
(410) 783-5888 |
Full Name | Thomas J Swope |
---|---|
Gender | Male |
Speciality | General Surgery |
Experience | 31 Years |
Location | 301 Saint Paul Pl, Baltimore, Maryland |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225074560 | NPI | - | NPPES |
S186 / 0003 | Other | MD | BLUECHOICE |
KG65ST / 685779-01 | Other | MD | BC / BS OF MD |
022501100 | Medicaid | MD |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | D0053154 (Maryland) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Mercy Medical Center Inc | Baltimore, MD | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
St Paul Place Specialists Inc | 7719882943 | 268 |
News Archive
Low-carb dieters now have an even sweeter way to melt off the pounds. Atkins Nutritionals, Inc., a leader in the weight-management category, announced today the launch of Atkins™ Candies, an indulgent line of bite-sized snacks that will be available nationwide beginning October 2013.
Multidrug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) pose a major problem for patients, doctors, and the pharmaceutical industry. To combat such bacteria, it is critical to understand how resistance is developed in the first place. It is commonly thought that an incomplete course of antibiotics would lead to resistance to that particular antibiotic by allowing the bacteria to make adaptive changes under less stringent conditions.
Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).
› Verified 3 days ago
Entity Name | St Paul Place Specialists Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1871549196 PECOS PAC ID: 7719882943 Enrollment ID: O20031202000084 |
News Archive
Low-carb dieters now have an even sweeter way to melt off the pounds. Atkins Nutritionals, Inc., a leader in the weight-management category, announced today the launch of Atkins™ Candies, an indulgent line of bite-sized snacks that will be available nationwide beginning October 2013.
Multidrug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) pose a major problem for patients, doctors, and the pharmaceutical industry. To combat such bacteria, it is critical to understand how resistance is developed in the first place. It is commonly thought that an incomplete course of antibiotics would lead to resistance to that particular antibiotic by allowing the bacteria to make adaptive changes under less stringent conditions.
Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Thomas J Swope, MD Po Box 64075, Baltimore, MD 21264-4075 Ph: () - | Thomas J Swope, MD 301 Saint Paul Pl, Pob 912, Baltimore, MD 21202-2102 Ph: (410) 332-9653 |
News Archive
Low-carb dieters now have an even sweeter way to melt off the pounds. Atkins Nutritionals, Inc., a leader in the weight-management category, announced today the launch of Atkins™ Candies, an indulgent line of bite-sized snacks that will be available nationwide beginning October 2013.
Multidrug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) pose a major problem for patients, doctors, and the pharmaceutical industry. To combat such bacteria, it is critical to understand how resistance is developed in the first place. It is commonly thought that an incomplete course of antibiotics would lead to resistance to that particular antibiotic by allowing the bacteria to make adaptive changes under less stringent conditions.
Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).
› Verified 3 days ago
Dr. Sabrina Christine Sopha, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-3580 | |
Dr. Samantha A Wolfe, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Baltimore, MD 21224 Phone: 410-550-2370 Fax: 410-955-0035 | |
Dr. Evan Wong, MD, MPH, FRCSC Surgery Medicare: Medicare Enrolled Practice Location: 1800 Orleans St Ste 6107, Baltimore, MD 21287 Phone: 410-955-2244 | |
Georgios Antonios Margonis, MD, PHD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1800 Orleans Street - Tower 110, Baltimore, MD 21287 Phone: 443-440-1103 | |
Bruce Robert Gibson, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Baltimore, MD 21224 Phone: 410-550-0100 | |
Kenzo Hirose, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-6190 | |
Josue Alvarez Casas, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 29 S Greene St Ste 200, Baltimore, MD 21201 Phone: 410-328-5408 |